nodes	percent_of_prediction	percent_of_DWPC	metapath
Amsacrine—TOP2A—Epirubicin—uterine cancer	0.205	0.314	CbGbCtD
Amsacrine—TOP2A—Etoposide—uterine cancer	0.16	0.244	CbGbCtD
Amsacrine—TOP2A—Doxorubicin—uterine cancer	0.109	0.167	CbGbCtD
Amsacrine—ABCB1—Progesterone—uterine cancer	0.0477	0.073	CbGbCtD
Amsacrine—CYP2D6—Progesterone—uterine cancer	0.045	0.0688	CbGbCtD
Amsacrine—ABCB1—Dactinomycin—uterine cancer	0.0378	0.0579	CbGbCtD
Amsacrine—ABCB1—Etoposide—uterine cancer	0.0214	0.0327	CbGbCtD
Amsacrine—ABCB1—Doxorubicin—uterine cancer	0.0146	0.0223	CbGbCtD
Amsacrine—CYP2D6—Doxorubicin—uterine cancer	0.0137	0.021	CbGbCtD
Amsacrine—NCOA3—myometrium—uterine cancer	0.00531	0.0668	CbGeAlD
Amsacrine—NCOA3—Validated nuclear estrogen receptor beta network—ESR2—uterine cancer	0.005	0.0789	CbGpPWpGaD
Amsacrine—NCOA3—uterine cervix—uterine cancer	0.00413	0.052	CbGeAlD
Amsacrine—NCOA3—smooth muscle tissue—uterine cancer	0.00401	0.0506	CbGeAlD
Amsacrine—NCOA3—decidua—uterine cancer	0.00393	0.0496	CbGeAlD
Amsacrine—NCOA3—renal system—uterine cancer	0.00386	0.0487	CbGeAlD
Amsacrine—NCOA3—endometrium—uterine cancer	0.00374	0.047	CbGeAlD
Amsacrine—NCOA3—mammalian vulva—uterine cancer	0.00361	0.0455	CbGeAlD
Amsacrine—NCOA3—uterus—uterine cancer	0.00344	0.0434	CbGeAlD
Amsacrine—TOP2A—myometrium—uterine cancer	0.00311	0.0392	CbGeAlD
Amsacrine—NCOA3—female reproductive system—uterine cancer	0.00309	0.039	CbGeAlD
Amsacrine—NCOA3—female gonad—uterine cancer	0.00282	0.0355	CbGeAlD
Amsacrine—NCOA3—EGF/EGFR Signaling Pathway—ERRFI1—uterine cancer	0.0028	0.0443	CbGpPWpGaD
Amsacrine—NCOA3—vagina—uterine cancer	0.0028	0.0352	CbGeAlD
Amsacrine—TOP2A—uterine cervix—uterine cancer	0.00242	0.0305	CbGeAlD
Amsacrine—TOP2A—decidua—uterine cancer	0.00231	0.0291	CbGeAlD
Amsacrine—NCOA3—EGF/EGFR Signaling Pathway—MAP3K4—uterine cancer	0.00224	0.0354	CbGpPWpGaD
Amsacrine—TOP2A—endometrium—uterine cancer	0.00219	0.0276	CbGeAlD
Amsacrine—TOP2A—mammalian vulva—uterine cancer	0.00212	0.0267	CbGeAlD
Amsacrine—TOP2A—uterus—uterine cancer	0.00202	0.0254	CbGeAlD
Amsacrine—NCOA3—lymph node—uterine cancer	0.00181	0.0228	CbGeAlD
Amsacrine—NCOA3—Validated nuclear estrogen receptor alpha network—PGR—uterine cancer	0.00178	0.0281	CbGpPWpGaD
Amsacrine—KCNH2—myometrium—uterine cancer	0.00174	0.022	CbGeAlD
Amsacrine—KCNH2—Hematopoietic Stem Cell Differentiation—CSF3—uterine cancer	0.00172	0.0271	CbGpPWpGaD
Amsacrine—TOP2A—female gonad—uterine cancer	0.00165	0.0208	CbGeAlD
Amsacrine—TOP2A—vagina—uterine cancer	0.00164	0.0207	CbGeAlD
Amsacrine—NCOA3—Idarubicin—Epirubicin—uterine cancer	0.00163	0.259	CbGdCrCtD
Amsacrine—NCOA3—Validated nuclear estrogen receptor alpha network—ESR2—uterine cancer	0.00157	0.0247	CbGpPWpGaD
Amsacrine—NCOA3—Idarubicin—Doxorubicin—uterine cancer	0.00151	0.239	CbGdCrCtD
Amsacrine—KCNH2—uterine cervix—uterine cancer	0.00136	0.0171	CbGeAlD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—MSH6—uterine cancer	0.00129	0.0204	CbGpPWpGaD
Amsacrine—NCOA3—FOXA1 transcription factor network—ESR1—uterine cancer	0.00128	0.0202	CbGpPWpGaD
Amsacrine—KCNH2—renal system—uterine cancer	0.00127	0.016	CbGeAlD
Amsacrine—KCNH2—endometrium—uterine cancer	0.00123	0.0155	CbGeAlD
Amsacrine—KCNH2—uterus—uterine cancer	0.00113	0.0143	CbGeAlD
Amsacrine—TOP2A—lymph node—uterine cancer	0.00106	0.0134	CbGeAlD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—MSH2—uterine cancer	0.00105	0.0165	CbGpPWpGaD
Amsacrine—NCOA3—Retinoic acid receptors-mediated signaling—EP300—uterine cancer	0.00104	0.0164	CbGpPWpGaD
Amsacrine—KCNH2—female reproductive system—uterine cancer	0.00102	0.0128	CbGeAlD
Amsacrine—NCOA3—Developmental Biology—PLXNA3—uterine cancer	0.000977	0.0154	CbGpPWpGaD
Amsacrine—KCNH2—Potassium Channels—ABCC9—uterine cancer	0.000965	0.0152	CbGpPWpGaD
Amsacrine—NCOA3—Validated nuclear estrogen receptor alpha network—ESR1—uterine cancer	0.00095	0.015	CbGpPWpGaD
Amsacrine—KCNH2—female gonad—uterine cancer	0.000926	0.0117	CbGeAlD
Amsacrine—KCNH2—vagina—uterine cancer	0.00092	0.0116	CbGeAlD
Amsacrine—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—FBXW7—uterine cancer	0.000913	0.0144	CbGpPWpGaD
Amsacrine—NCOA3—Androgen receptor signaling pathway—SMAD3—uterine cancer	0.000894	0.0141	CbGpPWpGaD
Amsacrine—TOP2A—Retinoblastoma (RB) in Cancer—MSH6—uterine cancer	0.00088	0.0139	CbGpPWpGaD
Amsacrine—NCOA3—FOXA1 transcription factor network—CDKN1B—uterine cancer	0.000871	0.0137	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—MAP3K4—uterine cancer	0.000861	0.0136	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	0.000778	0.0123	CbGpPWpGaD
Amsacrine—CYP2D6—renal system—uterine cancer	0.000775	0.00976	CbGeAlD
Amsacrine—ABCB1—myometrium—uterine cancer	0.000765	0.00964	CbGeAlD
Amsacrine—NCOA3—FOXA1 transcription factor network—EP300—uterine cancer	0.000765	0.0121	CbGpPWpGaD
Amsacrine—ABCB1—ABC-family proteins mediated transport—ABCC9—uterine cancer	0.000739	0.0117	CbGpPWpGaD
Amsacrine—TOP2A—Retinoblastoma (RB) in Cancer—RRM2—uterine cancer	0.000725	0.0114	CbGpPWpGaD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—STK11—uterine cancer	0.000715	0.0113	CbGpPWpGaD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—CYP19A1—uterine cancer	0.000715	0.0113	CbGpPWpGaD
Amsacrine—NCOA3—Retinoic acid receptors-mediated signaling—AKT1—uterine cancer	0.000628	0.00991	CbGpPWpGaD
Amsacrine—CYP2D6—female reproductive system—uterine cancer	0.00062	0.00781	CbGeAlD
Amsacrine—ABCB1—epithelium—uterine cancer	0.000601	0.00757	CbGeAlD
Amsacrine—ABCB1—uterine cervix—uterine cancer	0.000596	0.0075	CbGeAlD
Amsacrine—KCNH2—lymph node—uterine cancer	0.000595	0.00749	CbGeAlD
Amsacrine—ABCB1—decidua—uterine cancer	0.000567	0.00715	CbGeAlD
Amsacrine—TOP2A—Circadian rythm related genes—STAR—uterine cancer	0.000567	0.00895	CbGpPWpGaD
Amsacrine—NCOA3—Validated nuclear estrogen receptor alpha network—EP300—uterine cancer	0.000567	0.00895	CbGpPWpGaD
Amsacrine—CYP2D6—female gonad—uterine cancer	0.000564	0.00711	CbGeAlD
Amsacrine—NCOA3—Metabolism of lipids and lipoproteins—STAR—uterine cancer	0.000562	0.00888	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	0.000562	0.00888	CbGpPWpGaD
Amsacrine—ABCB1—renal system—uterine cancer	0.000557	0.00702	CbGeAlD
Amsacrine—ABCB1—endometrium—uterine cancer	0.000539	0.00678	CbGeAlD
Amsacrine—ABCB1—mammalian vulva—uterine cancer	0.000521	0.00656	CbGeAlD
Amsacrine—NCOA3—Developmental Biology—HNF1B—uterine cancer	0.000513	0.0081	CbGpPWpGaD
Amsacrine—TOP2A—Mitotic G1-G1/S phases—RRM2—uterine cancer	0.00051	0.00805	CbGpPWpGaD
Amsacrine—ABCB1—uterus—uterine cancer	0.000496	0.00625	CbGeAlD
Amsacrine—NCOA3—Transcriptional regulation of white adipocyte differentiation—EP300—uterine cancer	0.000489	0.00772	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—INHBA—uterine cancer	0.000481	0.0076	CbGpPWpGaD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—ESR1—uterine cancer	0.000478	0.00754	CbGpPWpGaD
Amsacrine—TOP2A—Gastric Cancer Network 2—CTNNB1—uterine cancer	0.000477	0.00754	CbGpPWpGaD
Amsacrine—NCOA3—Androgen receptor signaling pathway—CTNNB1—uterine cancer	0.000468	0.00739	CbGpPWpGaD
Amsacrine—TOP2A—Circadian rythm related genes—HNF1B—uterine cancer	0.000462	0.00729	CbGpPWpGaD
Amsacrine—NCOA3—Androgen receptor signaling pathway—PTEN—uterine cancer	0.000457	0.00721	CbGpPWpGaD
Amsacrine—ABCB1—female reproductive system—uterine cancer	0.000446	0.00562	CbGeAlD
Amsacrine—NCOA3—Androgen receptor signaling pathway—EP300—uterine cancer	0.000435	0.00687	CbGpPWpGaD
Amsacrine—TOP2A—Teniposide—Etoposide—uterine cancer	0.000429	0.0681	CbGdCrCtD
Amsacrine—TOP2A—Podofilox—Etoposide—uterine cancer	0.000429	0.0681	CbGdCrCtD
Amsacrine—KCNH2—Neuronal System—ABCC9—uterine cancer	0.000421	0.00665	CbGpPWpGaD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—CDH1—uterine cancer	0.000416	0.00656	CbGpPWpGaD
Amsacrine—Musculoskeletal pain—Epirubicin—uterine cancer	0.000414	0.0021	CcSEcCtD
Amsacrine—NCOA3—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	0.000413	0.00651	CbGpPWpGaD
Amsacrine—Dyspnoea—Medroxyprogesterone Acetate—uterine cancer	0.000411	0.00208	CcSEcCtD
Amsacrine—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—uterine cancer	0.000409	0.00646	CbGpPWpGaD
Amsacrine—Phosphatase alkaline increased—Epirubicin—uterine cancer	0.000409	0.00207	CcSEcCtD
Amsacrine—Infestation NOS—Etoposide—uterine cancer	0.000408	0.00207	CcSEcCtD
Amsacrine—Infestation—Etoposide—uterine cancer	0.000408	0.00207	CcSEcCtD
Amsacrine—Hyperuricaemia—Doxorubicin—uterine cancer	0.000408	0.00207	CcSEcCtD
Amsacrine—Anaemia—Dactinomycin—uterine cancer	0.000407	0.00206	CcSEcCtD
Amsacrine—Injection site reaction—Epirubicin—uterine cancer	0.000406	0.00206	CcSEcCtD
Amsacrine—ABCB1—female gonad—uterine cancer	0.000406	0.00511	CbGeAlD
Amsacrine—Urticaria—Progesterone—uterine cancer	0.000404	0.00205	CcSEcCtD
Amsacrine—ABCB1—vagina—uterine cancer	0.000404	0.00508	CbGeAlD
Amsacrine—Abdominal pain—Progesterone—uterine cancer	0.000402	0.00204	CcSEcCtD
Amsacrine—Body temperature increased—Progesterone—uterine cancer	0.000402	0.00204	CcSEcCtD
Amsacrine—Renal failure—Etoposide—uterine cancer	0.000401	0.00203	CcSEcCtD
Amsacrine—Decreased appetite—Medroxyprogesterone Acetate—uterine cancer	0.000401	0.00203	CcSEcCtD
Amsacrine—Blood bilirubin increased—Doxorubicin—uterine cancer	0.0004	0.00203	CcSEcCtD
Amsacrine—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.000398	0.00202	CcSEcCtD
Amsacrine—Stomatitis—Etoposide—uterine cancer	0.000398	0.00202	CcSEcCtD
Amsacrine—Jaundice—Etoposide—uterine cancer	0.000398	0.00202	CcSEcCtD
Amsacrine—Creatinine increased—Doxorubicin—uterine cancer	0.000397	0.00201	CcSEcCtD
Amsacrine—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.000397	0.00201	CcSEcCtD
Amsacrine—Leukopenia—Dactinomycin—uterine cancer	0.000394	0.002	CcSEcCtD
Amsacrine—Inflammation—Doxorubicin—uterine cancer	0.00039	0.00198	CcSEcCtD
Amsacrine—Blood urea increased—Epirubicin—uterine cancer	0.000386	0.00196	CcSEcCtD
Amsacrine—Hepatobiliary disease—Etoposide—uterine cancer	0.000386	0.00196	CcSEcCtD
Amsacrine—Blood uric acid increased—Doxorubicin—uterine cancer	0.000385	0.00195	CcSEcCtD
Amsacrine—Aplastic anaemia—Epirubicin—uterine cancer	0.000384	0.00195	CcSEcCtD
Amsacrine—Musculoskeletal pain—Doxorubicin—uterine cancer	0.000383	0.00194	CcSEcCtD
Amsacrine—Agranulocytosis—Etoposide—uterine cancer	0.000381	0.00193	CcSEcCtD
Amsacrine—Feeling abnormal—Medroxyprogesterone Acetate—uterine cancer	0.00038	0.00193	CcSEcCtD
Amsacrine—Phosphatase alkaline increased—Doxorubicin—uterine cancer	0.000378	0.00192	CcSEcCtD
Amsacrine—Gastrointestinal pain—Medroxyprogesterone Acetate—uterine cancer	0.000377	0.00191	CcSEcCtD
Amsacrine—Injection site reaction—Doxorubicin—uterine cancer	0.000376	0.00191	CcSEcCtD
Amsacrine—Hypersensitivity—Progesterone—uterine cancer	0.000375	0.0019	CcSEcCtD
Amsacrine—NCOA3—PPARA activates gene expression—EP300—uterine cancer	0.000368	0.0058	CbGpPWpGaD
Amsacrine—Urticaria—Medroxyprogesterone Acetate—uterine cancer	0.000366	0.00186	CcSEcCtD
Amsacrine—Asthenia—Progesterone—uterine cancer	0.000365	0.00185	CcSEcCtD
Amsacrine—Hypoaesthesia—Etoposide—uterine cancer	0.000364	0.00185	CcSEcCtD
Amsacrine—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.000364	0.00185	CcSEcCtD
Amsacrine—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.000364	0.00185	CcSEcCtD
Amsacrine—Urinary tract disorder—Etoposide—uterine cancer	0.000362	0.00183	CcSEcCtD
Amsacrine—NCOA3—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—uterine cancer	0.00036	0.00568	CbGpPWpGaD
Amsacrine—Urethral disorder—Etoposide—uterine cancer	0.000359	0.00182	CcSEcCtD
Amsacrine—Infection—Dactinomycin—uterine cancer	0.000357	0.00181	CcSEcCtD
Amsacrine—Blood urea increased—Doxorubicin—uterine cancer	0.000357	0.00181	CcSEcCtD
Amsacrine—Aplastic anaemia—Doxorubicin—uterine cancer	0.000355	0.0018	CcSEcCtD
Amsacrine—Sepsis—Epirubicin—uterine cancer	0.000355	0.0018	CcSEcCtD
Amsacrine—KCNH2—SIDS Susceptibility Pathways—YWHAE—uterine cancer	0.000352	0.00556	CbGpPWpGaD
Amsacrine—Thrombocytopenia—Dactinomycin—uterine cancer	0.000352	0.00178	CcSEcCtD
Amsacrine—TOP2A—Methyltestosterone—Medroxyprogesterone Acetate—uterine cancer	0.00035	0.0556	CbGdCrCtD
Amsacrine—Diarrhoea—Progesterone—uterine cancer	0.000348	0.00176	CcSEcCtD
Amsacrine—NCOA3—Metabolism—NDUFB11—uterine cancer	0.000346	0.00547	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—SRD5A2—uterine cancer	0.000346	0.00547	CbGpPWpGaD
Amsacrine—Phlebitis—Epirubicin—uterine cancer	0.000344	0.00175	CcSEcCtD
Amsacrine—Anorexia—Dactinomycin—uterine cancer	0.000343	0.00174	CcSEcCtD
Amsacrine—Blood alkaline phosphatase increased—Epirubicin—uterine cancer	0.000341	0.00173	CcSEcCtD
Amsacrine—Cardiac disorder—Etoposide—uterine cancer	0.00034	0.00172	CcSEcCtD
Amsacrine—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.000339	0.00172	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle—MLH3—uterine cancer	0.000337	0.00532	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	0.000336	0.00531	CbGpPWpGaD
Amsacrine—Dizziness—Progesterone—uterine cancer	0.000336	0.00171	CcSEcCtD
Amsacrine—Angiopathy—Etoposide—uterine cancer	0.000332	0.00168	CcSEcCtD
Amsacrine—Vascular purpura—Epirubicin—uterine cancer	0.000332	0.00168	CcSEcCtD
Amsacrine—NCOA3—EGF/EGFR Signaling Pathway—ERBB2—uterine cancer	0.000332	0.00523	CbGpPWpGaD
Amsacrine—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000331	0.00168	CcSEcCtD
Amsacrine—Hepatic failure—Epirubicin—uterine cancer	0.00033	0.00167	CcSEcCtD
Amsacrine—Mediastinal disorder—Etoposide—uterine cancer	0.00033	0.00167	CcSEcCtD
Amsacrine—Sepsis—Doxorubicin—uterine cancer	0.000328	0.00166	CcSEcCtD
Amsacrine—Cardiac failure congestive—Epirubicin—uterine cancer	0.000327	0.00166	CcSEcCtD
Amsacrine—KCNH2—SIDS Susceptibility Pathways—ESR2—uterine cancer	0.000325	0.00513	CbGpPWpGaD
Amsacrine—Alopecia—Etoposide—uterine cancer	0.000324	0.00164	CcSEcCtD
Amsacrine—Vomiting—Progesterone—uterine cancer	0.000323	0.00164	CcSEcCtD
Amsacrine—Rash—Progesterone—uterine cancer	0.000321	0.00163	CcSEcCtD
Amsacrine—Dermatitis—Progesterone—uterine cancer	0.00032	0.00162	CcSEcCtD
Amsacrine—Phlebitis—Doxorubicin—uterine cancer	0.000319	0.00162	CcSEcCtD
Amsacrine—Headache—Progesterone—uterine cancer	0.000319	0.00162	CcSEcCtD
Amsacrine—NCOA3—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	0.000318	0.00502	CbGpPWpGaD
Amsacrine—TOP2A—Gastric Cancer Network 2—TP53—uterine cancer	0.000318	0.00501	CbGpPWpGaD
Amsacrine—Blood alkaline phosphatase increased—Doxorubicin—uterine cancer	0.000316	0.0016	CcSEcCtD
Amsacrine—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000315	0.0016	CcSEcCtD
Amsacrine—Decreased appetite—Dactinomycin—uterine cancer	0.000312	0.00158	CcSEcCtD
Amsacrine—Fatigue—Dactinomycin—uterine cancer	0.00031	0.00157	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—EZH2—uterine cancer	0.000309	0.00487	CbGpPWpGaD
Amsacrine—Purpura—Epirubicin—uterine cancer	0.000308	0.00156	CcSEcCtD
Amsacrine—TOP2A—Mitotic G1-G1/S phases—CDKN2B—uterine cancer	0.000308	0.00485	CbGpPWpGaD
Amsacrine—Pain—Dactinomycin—uterine cancer	0.000307	0.00156	CcSEcCtD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—CTNNB1—uterine cancer	0.000307	0.00484	CbGpPWpGaD
Amsacrine—Vascular purpura—Doxorubicin—uterine cancer	0.000307	0.00156	CcSEcCtD
Amsacrine—Hepatic failure—Doxorubicin—uterine cancer	0.000305	0.00155	CcSEcCtD
Amsacrine—TOP2A—Methyltestosterone—Progesterone—uterine cancer	0.000305	0.0484	CbGdCrCtD
Amsacrine—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000305	0.00155	CcSEcCtD
Amsacrine—Lethargy—Epirubicin—uterine cancer	0.000303	0.00154	CcSEcCtD
Amsacrine—Cardiac failure congestive—Doxorubicin—uterine cancer	0.000303	0.00154	CcSEcCtD
Amsacrine—Nausea—Progesterone—uterine cancer	0.000302	0.00153	CcSEcCtD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—PTEN—uterine cancer	0.000299	0.00472	CbGpPWpGaD
Amsacrine—TOP2A—Circadian rythm related genes—EZH2—uterine cancer	0.000296	0.00468	CbGpPWpGaD
Amsacrine—Feeling abnormal—Dactinomycin—uterine cancer	0.000296	0.0015	CcSEcCtD
Amsacrine—Anaemia—Etoposide—uterine cancer	0.000295	0.00149	CcSEcCtD
Amsacrine—Gastrointestinal pain—Dactinomycin—uterine cancer	0.000294	0.00149	CcSEcCtD
Amsacrine—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000293	0.00149	CcSEcCtD
Amsacrine—Affect lability—Epirubicin—uterine cancer	0.000292	0.00148	CcSEcCtD
Amsacrine—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000291	0.00147	CcSEcCtD
Amsacrine—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.00029	0.00147	CcSEcCtD
Amsacrine—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000289	0.00146	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—ESR2—uterine cancer	0.000286	0.00452	CbGpPWpGaD
Amsacrine—Leukopenia—Etoposide—uterine cancer	0.000285	0.00145	CcSEcCtD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—EP300—uterine cancer	0.000285	0.0045	CbGpPWpGaD
Amsacrine—Purpura—Doxorubicin—uterine cancer	0.000285	0.00144	CcSEcCtD
Amsacrine—Abdominal pain—Dactinomycin—uterine cancer	0.000284	0.00144	CcSEcCtD
Amsacrine—Body temperature increased—Dactinomycin—uterine cancer	0.000284	0.00144	CcSEcCtD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—MAP3K4—uterine cancer	0.000284	0.00448	CbGpPWpGaD
Amsacrine—NCOA3—EGF/EGFR Signaling Pathway—PTEN—uterine cancer	0.000283	0.00446	CbGpPWpGaD
Amsacrine—Mood swings—Epirubicin—uterine cancer	0.000281	0.00143	CcSEcCtD
Amsacrine—Lethargy—Doxorubicin—uterine cancer	0.00028	0.00142	CcSEcCtD
Amsacrine—Blood creatinine increased—Epirubicin—uterine cancer	0.000278	0.00141	CcSEcCtD
Amsacrine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	0.000277	0.00437	CbGpPWpGaD
Amsacrine—Convulsion—Etoposide—uterine cancer	0.000276	0.0014	CcSEcCtD
Amsacrine—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000274	0.00139	CcSEcCtD
Amsacrine—CYP2D6—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	0.000273	0.00431	CbGpPWpGaD
Amsacrine—Affect lability—Doxorubicin—uterine cancer	0.00027	0.00137	CcSEcCtD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—VEGFA—uterine cancer	0.00027	0.00426	CbGpPWpGaD
Amsacrine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000269	0.00137	CcSEcCtD
Amsacrine—Aspartate aminotransferase increased—Epirubicin—uterine cancer	0.000267	0.00136	CcSEcCtD
Amsacrine—Hypersensitivity—Dactinomycin—uterine cancer	0.000265	0.00134	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle, Mitotic—NDC80—uterine cancer	0.000264	0.00416	CbGpPWpGaD
Amsacrine—NCOA3—Androgen receptor signaling pathway—AKT1—uterine cancer	0.000263	0.00415	CbGpPWpGaD
Amsacrine—Confusional state—Etoposide—uterine cancer	0.000262	0.00133	CcSEcCtD
Amsacrine—ABCB1—lymph node—uterine cancer	0.000261	0.00329	CbGeAlD
Amsacrine—Mood swings—Doxorubicin—uterine cancer	0.00026	0.00132	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—STK11—uterine cancer	0.00026	0.0041	CbGpPWpGaD
Amsacrine—Infection—Etoposide—uterine cancer	0.000258	0.00131	CcSEcCtD
Amsacrine—Asthenia—Dactinomycin—uterine cancer	0.000258	0.00131	CcSEcCtD
Amsacrine—Blood creatinine increased—Doxorubicin—uterine cancer	0.000257	0.0013	CcSEcCtD
Amsacrine—Dysphagia—Epirubicin—uterine cancer	0.000256	0.0013	CcSEcCtD
Amsacrine—Thrombocytopenia—Etoposide—uterine cancer	0.000255	0.00129	CcSEcCtD
Amsacrine—Tachycardia—Etoposide—uterine cancer	0.000254	0.00129	CcSEcCtD
Amsacrine—Skin disorder—Etoposide—uterine cancer	0.000253	0.00128	CcSEcCtD
Amsacrine—NCOA3—Metabolism—STAR—uterine cancer	0.00025	0.00395	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—AKR1B1—uterine cancer	0.00025	0.00395	CbGpPWpGaD
Amsacrine—Anorexia—Etoposide—uterine cancer	0.000248	0.00126	CcSEcCtD
Amsacrine—NCOA3—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—uterine cancer	0.000248	0.00391	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	0.000248	0.00391	CbGpPWpGaD
Amsacrine—Aspartate aminotransferase increased—Doxorubicin—uterine cancer	0.000247	0.00125	CcSEcCtD
Amsacrine—Diarrhoea—Dactinomycin—uterine cancer	0.000246	0.00125	CcSEcCtD
Amsacrine—Pancytopenia—Epirubicin—uterine cancer	0.000244	0.00124	CcSEcCtD
Amsacrine—Hypotension—Etoposide—uterine cancer	0.000243	0.00123	CcSEcCtD
Amsacrine—Dysphagia—Doxorubicin—uterine cancer	0.000237	0.0012	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle—NDC80—uterine cancer	0.000236	0.00372	CbGpPWpGaD
Amsacrine—Paraesthesia—Etoposide—uterine cancer	0.000234	0.00118	CcSEcCtD
Amsacrine—Weight increased—Epirubicin—uterine cancer	0.000233	0.00118	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN2B—uterine cancer	0.000233	0.00368	CbGpPWpGaD
Amsacrine—Weight decreased—Epirubicin—uterine cancer	0.000232	0.00118	CcSEcCtD
Amsacrine—Dyspnoea—Etoposide—uterine cancer	0.000232	0.00118	CcSEcCtD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—KRAS—uterine cancer	0.00023	0.00362	CbGpPWpGaD
Amsacrine—Infestation NOS—Epirubicin—uterine cancer	0.000229	0.00116	CcSEcCtD
Amsacrine—Infestation—Epirubicin—uterine cancer	0.000229	0.00116	CcSEcCtD
Amsacrine—Vomiting—Dactinomycin—uterine cancer	0.000229	0.00116	CcSEcCtD
Amsacrine—NCOA3—Developmental Biology—SMAD3—uterine cancer	0.000227	0.00358	CbGpPWpGaD
Amsacrine—Rash—Dactinomycin—uterine cancer	0.000227	0.00115	CcSEcCtD
Amsacrine—Decreased appetite—Etoposide—uterine cancer	0.000226	0.00115	CcSEcCtD
Amsacrine—Pancytopenia—Doxorubicin—uterine cancer	0.000225	0.00114	CcSEcCtD
Amsacrine—Renal failure—Epirubicin—uterine cancer	0.000225	0.00114	CcSEcCtD
Amsacrine—Gastrointestinal disorder—Etoposide—uterine cancer	0.000225	0.00114	CcSEcCtD
Amsacrine—CYP2D6—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	0.000224	0.00354	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle, Mitotic—POLD1—uterine cancer	0.000224	0.00354	CbGpPWpGaD
Amsacrine—Fatigue—Etoposide—uterine cancer	0.000224	0.00114	CcSEcCtD
Amsacrine—TOP2A—Daunorubicin—Epirubicin—uterine cancer	0.000224	0.0355	CbGdCrCtD
Amsacrine—TOP2A—Doxorubicin—Epirubicin—uterine cancer	0.000224	0.0355	CbGdCrCtD
Amsacrine—TOP2A—Idarubicin—Epirubicin—uterine cancer	0.000224	0.0355	CbGdCrCtD
Amsacrine—Jaundice—Epirubicin—uterine cancer	0.000223	0.00113	CcSEcCtD
Amsacrine—Stomatitis—Epirubicin—uterine cancer	0.000223	0.00113	CcSEcCtD
Amsacrine—Pain—Etoposide—uterine cancer	0.000222	0.00113	CcSEcCtD
Amsacrine—TOP2A—Retinoblastoma (RB) in Cancer—CDKN1B—uterine cancer	0.000221	0.00349	CbGpPWpGaD
Amsacrine—Haematuria—Epirubicin—uterine cancer	0.000218	0.00111	CcSEcCtD
Amsacrine—NCOA3—EGF/EGFR Signaling Pathway—KRAS—uterine cancer	0.000217	0.00343	CbGpPWpGaD
Amsacrine—Hepatobiliary disease—Epirubicin—uterine cancer	0.000216	0.0011	CcSEcCtD
Amsacrine—Weight increased—Doxorubicin—uterine cancer	0.000216	0.0011	CcSEcCtD
Amsacrine—Weight decreased—Doxorubicin—uterine cancer	0.000215	0.00109	CcSEcCtD
Amsacrine—Feeling abnormal—Etoposide—uterine cancer	0.000214	0.00109	CcSEcCtD
Amsacrine—Nausea—Dactinomycin—uterine cancer	0.000213	0.00108	CcSEcCtD
Amsacrine—Agranulocytosis—Epirubicin—uterine cancer	0.000213	0.00108	CcSEcCtD
Amsacrine—Gastrointestinal pain—Etoposide—uterine cancer	0.000213	0.00108	CcSEcCtD
Amsacrine—Infestation—Doxorubicin—uterine cancer	0.000212	0.00107	CcSEcCtD
Amsacrine—Infestation NOS—Doxorubicin—uterine cancer	0.000212	0.00107	CcSEcCtD
Amsacrine—CYP2D6—Metapathway biotransformation—AKR1B10—uterine cancer	0.000211	0.00334	CbGpPWpGaD
Amsacrine—Bradycardia—Epirubicin—uterine cancer	0.000209	0.00106	CcSEcCtD
Amsacrine—Renal failure—Doxorubicin—uterine cancer	0.000208	0.00105	CcSEcCtD
Amsacrine—TOP2A—Daunorubicin—Doxorubicin—uterine cancer	0.000207	0.0329	CbGdCrCtD
Amsacrine—TOP2A—Epirubicin—Doxorubicin—uterine cancer	0.000207	0.0329	CbGdCrCtD
Amsacrine—TOP2A—Idarubicin—Doxorubicin—uterine cancer	0.000207	0.0329	CbGdCrCtD
Amsacrine—Urticaria—Etoposide—uterine cancer	0.000207	0.00105	CcSEcCtD
Amsacrine—Haemoglobin—Epirubicin—uterine cancer	0.000206	0.00105	CcSEcCtD
Amsacrine—Jaundice—Doxorubicin—uterine cancer	0.000206	0.00105	CcSEcCtD
Amsacrine—Stomatitis—Doxorubicin—uterine cancer	0.000206	0.00105	CcSEcCtD
Amsacrine—Abdominal pain—Etoposide—uterine cancer	0.000206	0.00104	CcSEcCtD
Amsacrine—Body temperature increased—Etoposide—uterine cancer	0.000206	0.00104	CcSEcCtD
Amsacrine—Hepatitis—Epirubicin—uterine cancer	0.000205	0.00104	CcSEcCtD
Amsacrine—Haemorrhage—Epirubicin—uterine cancer	0.000205	0.00104	CcSEcCtD
Amsacrine—Hypoaesthesia—Epirubicin—uterine cancer	0.000204	0.00104	CcSEcCtD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—TP53—uterine cancer	0.000204	0.00322	CbGpPWpGaD
Amsacrine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	0.000204	0.00321	CbGpPWpGaD
Amsacrine—Urinary tract disorder—Epirubicin—uterine cancer	0.000203	0.00103	CcSEcCtD
Amsacrine—Haematuria—Doxorubicin—uterine cancer	0.000202	0.00102	CcSEcCtD
Amsacrine—Connective tissue disorder—Epirubicin—uterine cancer	0.000202	0.00102	CcSEcCtD
Amsacrine—Urethral disorder—Epirubicin—uterine cancer	0.000201	0.00102	CcSEcCtD
Amsacrine—CYP2D6—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	0.000201	0.00317	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—POLD1—uterine cancer	0.000201	0.00317	CbGpPWpGaD
Amsacrine—Hepatobiliary disease—Doxorubicin—uterine cancer	0.0002	0.00101	CcSEcCtD
Amsacrine—TOP2A—Norethindrone—Progesterone—uterine cancer	0.000199	0.0316	CbGdCrCtD
Amsacrine—Agranulocytosis—Doxorubicin—uterine cancer	0.000197	0.001	CcSEcCtD
Amsacrine—NCOA3—Metabolism—POLD1—uterine cancer	0.000197	0.0031	CbGpPWpGaD
Amsacrine—CYP2D6—Metapathway biotransformation—AKR1B1—uterine cancer	0.000196	0.0031	CbGpPWpGaD
Amsacrine—Bradycardia—Doxorubicin—uterine cancer	0.000193	0.000981	CcSEcCtD
Amsacrine—Hypersensitivity—Etoposide—uterine cancer	0.000192	0.000972	CcSEcCtD
Amsacrine—Haemoglobin—Doxorubicin—uterine cancer	0.000191	0.000968	CcSEcCtD
Amsacrine—Cardiac disorder—Epirubicin—uterine cancer	0.00019	0.000966	CcSEcCtD
Amsacrine—Haemorrhage—Doxorubicin—uterine cancer	0.00019	0.000963	CcSEcCtD
Amsacrine—Hepatitis—Doxorubicin—uterine cancer	0.00019	0.000963	CcSEcCtD
Amsacrine—Hypoaesthesia—Doxorubicin—uterine cancer	0.000189	0.000958	CcSEcCtD
Amsacrine—Urinary tract disorder—Doxorubicin—uterine cancer	0.000188	0.000951	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle, Mitotic—RRM2—uterine cancer	0.000187	0.00295	CbGpPWpGaD
Amsacrine—Asthenia—Etoposide—uterine cancer	0.000187	0.000947	CcSEcCtD
Amsacrine—Connective tissue disorder—Doxorubicin—uterine cancer	0.000187	0.000947	CcSEcCtD
Amsacrine—Angiopathy—Epirubicin—uterine cancer	0.000186	0.000944	CcSEcCtD
Amsacrine—Urethral disorder—Doxorubicin—uterine cancer	0.000186	0.000944	CcSEcCtD
Amsacrine—NCOA3—Developmental Biology—MET—uterine cancer	0.000186	0.00293	CbGpPWpGaD
Amsacrine—Mediastinal disorder—Epirubicin—uterine cancer	0.000185	0.000938	CcSEcCtD
Amsacrine—NCOA3—EGF/EGFR Signaling Pathway—HRAS—uterine cancer	0.000185	0.00291	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—AKR1C1—uterine cancer	0.000184	0.0029	CbGpPWpGaD
Amsacrine—Arrhythmia—Epirubicin—uterine cancer	0.000183	0.00093	CcSEcCtD
Amsacrine—Alopecia—Epirubicin—uterine cancer	0.000181	0.00092	CcSEcCtD
Amsacrine—Mental disorder—Epirubicin—uterine cancer	0.00018	0.000912	CcSEcCtD
Amsacrine—Malnutrition—Epirubicin—uterine cancer	0.000179	0.000906	CcSEcCtD
Amsacrine—Diarrhoea—Etoposide—uterine cancer	0.000178	0.000903	CcSEcCtD
Amsacrine—Cardiac disorder—Doxorubicin—uterine cancer	0.000176	0.000894	CcSEcCtD
Amsacrine—TOP2A—Mitotic G1-G1/S phases—CDKN2A—uterine cancer	0.000176	0.00278	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—ESR1—uterine cancer	0.000174	0.00274	CbGpPWpGaD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—AKT1—uterine cancer	0.000172	0.00272	CbGpPWpGaD
Amsacrine—Angiopathy—Doxorubicin—uterine cancer	0.000172	0.000874	CcSEcCtD
Amsacrine—Dizziness—Etoposide—uterine cancer	0.000172	0.000872	CcSEcCtD
Amsacrine—Mediastinal disorder—Doxorubicin—uterine cancer	0.000171	0.000868	CcSEcCtD
Amsacrine—Arrhythmia—Doxorubicin—uterine cancer	0.00017	0.00086	CcSEcCtD
Amsacrine—Vision blurred—Epirubicin—uterine cancer	0.000168	0.000854	CcSEcCtD
Amsacrine—Alopecia—Doxorubicin—uterine cancer	0.000168	0.000851	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle—RRM2—uterine cancer	0.000167	0.00264	CbGpPWpGaD
Amsacrine—Mental disorder—Doxorubicin—uterine cancer	0.000166	0.000844	CcSEcCtD
Amsacrine—Vomiting—Etoposide—uterine cancer	0.000165	0.000839	CcSEcCtD
Amsacrine—Malnutrition—Doxorubicin—uterine cancer	0.000165	0.000838	CcSEcCtD
Amsacrine—Anaemia—Epirubicin—uterine cancer	0.000165	0.000838	CcSEcCtD
Amsacrine—CYP2D6—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	0.000165	0.00261	CbGpPWpGaD
Amsacrine—Rash—Etoposide—uterine cancer	0.000164	0.000832	CcSEcCtD
Amsacrine—ABCB1—HIF-1-alpha transcription factor network—SMAD3—uterine cancer	0.000164	0.00259	CbGpPWpGaD
Amsacrine—Dermatitis—Etoposide—uterine cancer	0.000164	0.000831	CcSEcCtD
Amsacrine—NCOA3—Metabolism—RRM2—uterine cancer	0.000164	0.00259	CbGpPWpGaD
Amsacrine—Headache—Etoposide—uterine cancer	0.000163	0.000827	CcSEcCtD
Amsacrine—NCOA3—EGF/EGFR Signaling Pathway—AKT1—uterine cancer	0.000163	0.00257	CbGpPWpGaD
Amsacrine—Leukopenia—Epirubicin—uterine cancer	0.00016	0.000811	CcSEcCtD
Amsacrine—NCOA3—Metabolism—DCN—uterine cancer	0.000159	0.00251	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—INHBA—uterine cancer	0.000158	0.0025	CbGpPWpGaD
Amsacrine—TOP2A—Levonorgestrel—Progesterone—uterine cancer	0.000158	0.0251	CbGdCrCtD
Amsacrine—Vision blurred—Doxorubicin—uterine cancer	0.000156	0.00079	CcSEcCtD
Amsacrine—TOP2A—Mitotic G1-G1/S phases—CDKN1B—uterine cancer	0.000156	0.00246	CbGpPWpGaD
Amsacrine—Convulsion—Epirubicin—uterine cancer	0.000155	0.000785	CcSEcCtD
Amsacrine—Nausea—Etoposide—uterine cancer	0.000155	0.000784	CcSEcCtD
Amsacrine—Anaemia—Doxorubicin—uterine cancer	0.000153	0.000775	CcSEcCtD
Amsacrine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000151	0.000766	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle, Mitotic—YWHAE—uterine cancer	0.00015	0.00237	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—CYP11A1—uterine cancer	0.00015	0.00237	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—MLH1—uterine cancer	0.000148	0.00234	CbGpPWpGaD
Amsacrine—Leukopenia—Doxorubicin—uterine cancer	0.000148	0.000751	CcSEcCtD
Amsacrine—Confusional state—Epirubicin—uterine cancer	0.000147	0.000746	CcSEcCtD
Amsacrine—Infection—Epirubicin—uterine cancer	0.000145	0.000735	CcSEcCtD
Amsacrine—CYP2D6—Metapathway biotransformation—AKR1C1—uterine cancer	0.000144	0.00228	CbGpPWpGaD
Amsacrine—Convulsion—Doxorubicin—uterine cancer	0.000143	0.000726	CcSEcCtD
Amsacrine—Thrombocytopenia—Epirubicin—uterine cancer	0.000143	0.000724	CcSEcCtD
Amsacrine—Tachycardia—Epirubicin—uterine cancer	0.000142	0.000722	CcSEcCtD
Amsacrine—Skin disorder—Epirubicin—uterine cancer	0.000142	0.000718	CcSEcCtD
Amsacrine—NCOA3—Metabolism—AKR1C3—uterine cancer	0.000142	0.00223	CbGpPWpGaD
Amsacrine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.00014	0.000709	CcSEcCtD
Amsacrine—TOP2A—Retinoblastoma (RB) in Cancer—TP53—uterine cancer	0.000139	0.0022	CbGpPWpGaD
Amsacrine—Anorexia—Epirubicin—uterine cancer	0.000139	0.000705	CcSEcCtD
Amsacrine—KCNH2—SIDS Susceptibility Pathways—CXCL8—uterine cancer	0.000137	0.00217	CbGpPWpGaD
Amsacrine—Hypotension—Epirubicin—uterine cancer	0.000136	0.000691	CcSEcCtD
Amsacrine—Confusional state—Doxorubicin—uterine cancer	0.000136	0.00069	CcSEcCtD
Amsacrine—NCOA3—Developmental Biology—ERBB2—uterine cancer	0.000136	0.00214	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—YWHAE—uterine cancer	0.000134	0.00212	CbGpPWpGaD
Amsacrine—Infection—Doxorubicin—uterine cancer	0.000134	0.00068	CcSEcCtD
Amsacrine—Thrombocytopenia—Doxorubicin—uterine cancer	0.000132	0.00067	CcSEcCtD
Amsacrine—Tachycardia—Doxorubicin—uterine cancer	0.000132	0.000668	CcSEcCtD
Amsacrine—Skin disorder—Doxorubicin—uterine cancer	0.000131	0.000665	CcSEcCtD
Amsacrine—Paraesthesia—Epirubicin—uterine cancer	0.000131	0.000664	CcSEcCtD
Amsacrine—Dyspnoea—Epirubicin—uterine cancer	0.00013	0.000659	CcSEcCtD
Amsacrine—Anorexia—Doxorubicin—uterine cancer	0.000129	0.000652	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	0.000127	0.00201	CbGpPWpGaD
Amsacrine—Decreased appetite—Epirubicin—uterine cancer	0.000127	0.000643	CcSEcCtD
Amsacrine—CYP2D6—Metapathway biotransformation—GPX3—uterine cancer	0.000127	0.002	CbGpPWpGaD
Amsacrine—KCNH2—SIDS Susceptibility Pathways—CTNNB1—uterine cancer	0.000127	0.002	CbGpPWpGaD
Amsacrine—Hypotension—Doxorubicin—uterine cancer	0.000126	0.000639	CcSEcCtD
Amsacrine—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000126	0.000639	CcSEcCtD
Amsacrine—Fatigue—Epirubicin—uterine cancer	0.000126	0.000638	CcSEcCtD
Amsacrine—Pain—Epirubicin—uterine cancer	0.000125	0.000632	CcSEcCtD
Amsacrine—Paraesthesia—Doxorubicin—uterine cancer	0.000121	0.000614	CcSEcCtD
Amsacrine—Dyspnoea—Doxorubicin—uterine cancer	0.00012	0.00061	CcSEcCtD
Amsacrine—Feeling abnormal—Epirubicin—uterine cancer	0.00012	0.000609	CcSEcCtD
Amsacrine—Gastrointestinal pain—Epirubicin—uterine cancer	0.000119	0.000605	CcSEcCtD
Amsacrine—CYP2D6—Biological oxidations—CYP11A1—uterine cancer	0.000119	0.00188	CbGpPWpGaD
Amsacrine—NCOA3—Developmental Biology—CTNNB1—uterine cancer	0.000119	0.00188	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	0.000118	0.00186	CbGpPWpGaD
Amsacrine—KCNH2—SIDS Susceptibility Pathways—EP300—uterine cancer	0.000118	0.00186	CbGpPWpGaD
Amsacrine—CYP2D6—Metapathway biotransformation—CYP11A1—uterine cancer	0.000118	0.00186	CbGpPWpGaD
Amsacrine—Decreased appetite—Doxorubicin—uterine cancer	0.000117	0.000595	CcSEcCtD
Amsacrine—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000116	0.000591	CcSEcCtD
Amsacrine—Fatigue—Doxorubicin—uterine cancer	0.000116	0.00059	CcSEcCtD
Amsacrine—Urticaria—Epirubicin—uterine cancer	0.000116	0.000588	CcSEcCtD
Amsacrine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—uterine cancer	0.000115	0.00182	CbGpPWpGaD
Amsacrine—Pain—Doxorubicin—uterine cancer	0.000115	0.000585	CcSEcCtD
Amsacrine—Abdominal pain—Epirubicin—uterine cancer	0.000115	0.000585	CcSEcCtD
Amsacrine—Body temperature increased—Epirubicin—uterine cancer	0.000115	0.000585	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle, Mitotic—CDKN2B—uterine cancer	0.000113	0.00178	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	0.000111	0.00176	CbGpPWpGaD
Amsacrine—KCNH2—SIDS Susceptibility Pathways—VEGFA—uterine cancer	0.000111	0.00176	CbGpPWpGaD
Amsacrine—Feeling abnormal—Doxorubicin—uterine cancer	0.000111	0.000564	CcSEcCtD
Amsacrine—CYP2D6—Metapathway biotransformation—AKR1C3—uterine cancer	0.000111	0.00175	CbGpPWpGaD
Amsacrine—NCOA3—Developmental Biology—EP300—uterine cancer	0.000111	0.00174	CbGpPWpGaD
Amsacrine—Gastrointestinal pain—Doxorubicin—uterine cancer	0.00011	0.00056	CcSEcCtD
Amsacrine—NCOA3—Metabolism—STK11—uterine cancer	0.00011	0.00174	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—CYP19A1—uterine cancer	0.00011	0.00174	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	0.000109	0.00171	CbGpPWpGaD
Amsacrine—Hypersensitivity—Epirubicin—uterine cancer	0.000107	0.000545	CcSEcCtD
Amsacrine—Urticaria—Doxorubicin—uterine cancer	0.000107	0.000544	CcSEcCtD
Amsacrine—Abdominal pain—Doxorubicin—uterine cancer	0.000107	0.000541	CcSEcCtD
Amsacrine—Body temperature increased—Doxorubicin—uterine cancer	0.000107	0.000541	CcSEcCtD
Amsacrine—NCOA3—Developmental Biology—VEGFA—uterine cancer	0.000105	0.00165	CbGpPWpGaD
Amsacrine—Asthenia—Epirubicin—uterine cancer	0.000105	0.000531	CcSEcCtD
Amsacrine—TOP2A—Circadian rythm related genes—PTEN—uterine cancer	0.000104	0.00165	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	0.000104	0.00164	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	0.000103	0.00163	CbGpPWpGaD
Amsacrine—NCOA3—Developmental Biology—NRAS—uterine cancer	0.000103	0.00163	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—uterine cancer	0.000102	0.0016	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—CDKN2B—uterine cancer	0.000101	0.00159	CbGpPWpGaD
Amsacrine—Diarrhoea—Epirubicin—uterine cancer	9.98e-05	0.000506	CcSEcCtD
Amsacrine—TOP2A—Circadian rythm related genes—EP300—uterine cancer	9.95e-05	0.00157	CbGpPWpGaD
Amsacrine—Hypersensitivity—Doxorubicin—uterine cancer	9.94e-05	0.000504	CcSEcCtD
Amsacrine—NCOA3—Metabolism of lipids and lipoproteins—EP300—uterine cancer	9.87e-05	0.00156	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	9.81e-05	0.00155	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle, Mitotic—BIRC5—uterine cancer	9.73e-05	0.00154	CbGpPWpGaD
Amsacrine—Asthenia—Doxorubicin—uterine cancer	9.68e-05	0.000491	CcSEcCtD
Amsacrine—Dizziness—Epirubicin—uterine cancer	9.64e-05	0.000489	CcSEcCtD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—uterine cancer	9.42e-05	0.00149	CbGpPWpGaD
Amsacrine—Vomiting—Epirubicin—uterine cancer	9.27e-05	0.00047	CcSEcCtD
Amsacrine—Diarrhoea—Doxorubicin—uterine cancer	9.23e-05	0.000468	CcSEcCtD
Amsacrine—Rash—Epirubicin—uterine cancer	9.19e-05	0.000466	CcSEcCtD
Amsacrine—Dermatitis—Epirubicin—uterine cancer	9.19e-05	0.000466	CcSEcCtD
Amsacrine—Headache—Epirubicin—uterine cancer	9.13e-05	0.000463	CcSEcCtD
Amsacrine—Dizziness—Doxorubicin—uterine cancer	8.92e-05	0.000453	CcSEcCtD
Amsacrine—NCOA3—Developmental Biology—KRAS—uterine cancer	8.9e-05	0.0014	CbGpPWpGaD
Amsacrine—CYP2D6—Biological oxidations—CYP19A1—uterine cancer	8.77e-05	0.00138	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—BIRC5—uterine cancer	8.7e-05	0.00137	CbGpPWpGaD
Amsacrine—Nausea—Epirubicin—uterine cancer	8.66e-05	0.000439	CcSEcCtD
Amsacrine—CYP2D6—Metapathway biotransformation—CYP19A1—uterine cancer	8.65e-05	0.00137	CbGpPWpGaD
Amsacrine—Vomiting—Doxorubicin—uterine cancer	8.58e-05	0.000435	CcSEcCtD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—uterine cancer	8.56e-05	0.00135	CbGpPWpGaD
Amsacrine—Rash—Doxorubicin—uterine cancer	8.51e-05	0.000431	CcSEcCtD
Amsacrine—Dermatitis—Doxorubicin—uterine cancer	8.5e-05	0.000431	CcSEcCtD
Amsacrine—Headache—Doxorubicin—uterine cancer	8.45e-05	0.000429	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	8.34e-05	0.00132	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—MTHFR—uterine cancer	8.28e-05	0.00131	CbGpPWpGaD
Amsacrine—ABCB1—Allograft Rejection—CXCL8—uterine cancer	8.06e-05	0.00127	CbGpPWpGaD
Amsacrine—Nausea—Doxorubicin—uterine cancer	8.01e-05	0.000406	CcSEcCtD
Amsacrine—ABCB1—HIF-1-alpha transcription factor network—EP300—uterine cancer	7.98e-05	0.00126	CbGpPWpGaD
Amsacrine—ABCB1—Transmembrane transport of small molecules—ABCC9—uterine cancer	7.72e-05	0.00122	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—uterine cancer	7.67e-05	0.00121	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	7.67e-05	0.00121	CbGpPWpGaD
Amsacrine—NCOA3—Developmental Biology—HRAS—uterine cancer	7.56e-05	0.00119	CbGpPWpGaD
Amsacrine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—uterine cancer	7.56e-05	0.00119	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	7.42e-05	0.00117	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	7.3e-05	0.00115	CbGpPWpGaD
Amsacrine—TOP2A—Circadian rythm related genes—TP53—uterine cancer	7.12e-05	0.00112	CbGpPWpGaD
Amsacrine—NCOA3—Developmental Biology—AKT1—uterine cancer	6.68e-05	0.00105	CbGpPWpGaD
Amsacrine—ABCB1—Allograft Rejection—VEGFA—uterine cancer	6.55e-05	0.00103	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle, Mitotic—CDKN2A—uterine cancer	6.45e-05	0.00102	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	6.26e-05	0.000988	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—CDKN2A—uterine cancer	5.77e-05	0.00091	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—uterine cancer	5.72e-05	0.000902	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle, Mitotic—CDKN1B—uterine cancer	5.71e-05	0.000902	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—CDKN1B—uterine cancer	5.11e-05	0.000806	CbGpPWpGaD
Amsacrine—KCNH2—Neuronal System—HRAS—uterine cancer	5.06e-05	0.000798	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle, Mitotic—EP300—uterine cancer	5.02e-05	0.000792	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—NDUFB11—uterine cancer	5e-05	0.000789	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—SRD5A2—uterine cancer	5e-05	0.000789	CbGpPWpGaD
Amsacrine—ABCB1—HIF-1-alpha transcription factor network—AKT1—uterine cancer	4.82e-05	0.000761	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—NDUFB11—uterine cancer	4.71e-05	0.000744	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—SRD5A2—uterine cancer	4.71e-05	0.000744	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—PTEN—uterine cancer	4.61e-05	0.000727	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—EP300—uterine cancer	4.49e-05	0.000708	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—EP300—uterine cancer	4.4e-05	0.000694	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	4.2e-05	0.000662	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	3.89e-05	0.000613	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	3.67e-05	0.000579	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—AKR1B1—uterine cancer	3.62e-05	0.000571	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—STAR—uterine cancer	3.62e-05	0.000571	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	3.58e-05	0.000565	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	3.41e-05	0.000539	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—STAR—uterine cancer	3.41e-05	0.000538	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—AKR1B1—uterine cancer	3.41e-05	0.000538	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—PIK3CA—uterine cancer	3.25e-05	0.000513	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	3.23e-05	0.00051	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—TP53—uterine cancer	3.21e-05	0.000507	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—POLD1—uterine cancer	2.84e-05	0.000448	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	2.75e-05	0.000434	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—POLD1—uterine cancer	2.67e-05	0.000422	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—AKT1—uterine cancer	2.66e-05	0.000419	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—AKR1C1—uterine cancer	2.65e-05	0.000419	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	2.52e-05	0.000398	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—AKR1C1—uterine cancer	2.5e-05	0.000395	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	2.44e-05	0.000385	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—RRM2—uterine cancer	2.37e-05	0.000373	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—DCN—uterine cancer	2.3e-05	0.000362	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—RRM2—uterine cancer	2.23e-05	0.000352	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—DCN—uterine cancer	2.16e-05	0.000342	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—CYP11A1—uterine cancer	2.16e-05	0.000341	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	2.06e-05	0.000325	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—AKR1C3—uterine cancer	2.04e-05	0.000322	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—CYP11A1—uterine cancer	2.04e-05	0.000322	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—AKR1C3—uterine cancer	1.93e-05	0.000304	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—STK11—uterine cancer	1.59e-05	0.000251	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—CYP19A1—uterine cancer	1.59e-05	0.000251	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—STK11—uterine cancer	1.5e-05	0.000237	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—CYP19A1—uterine cancer	1.5e-05	0.000237	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—MTHFR—uterine cancer	1.2e-05	0.000189	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—MTHFR—uterine cancer	1.13e-05	0.000178	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—PTEN—uterine cancer	6.65e-06	0.000105	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—EP300—uterine cancer	6.35e-06	0.0001	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—PTEN—uterine cancer	6.27e-06	9.9e-05	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—EP300—uterine cancer	5.98e-06	9.44e-05	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—PIK3CA—uterine cancer	4.69e-06	7.41e-05	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—PIK3CA—uterine cancer	4.42e-06	6.98e-05	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—AKT1—uterine cancer	3.83e-06	6.05e-05	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—AKT1—uterine cancer	3.61e-06	5.7e-05	CbGpPWpGaD
